askme

Shanghai Baoteng Biomedical Technology Co., Ltd. is a high-tech biomedical enterprise founded by a group of outstanding Chinese-American scientists in the biomedical field, together with domestic market and management teams. The company was established in August 2008 with a registered capital of RMB 68.9 million. It currently owns nineteen subsidiaries (including Shanghai Baoteng Medical Laboratory Co., Ltd., Shanghai Zhangjiang Translational Medicine R&D Center, Shanghai Baoteng Health Management Co., Ltd., etc.) and is a leading enterprise in the field of precision medicine in China.

▲Undertaker of National 863 Program (Key Technology Research on Development and Utilization of Biomedical Big Data)
▲Undertaker of National Molecular Medicine Translational Science Center
▲National Postdoctoral Research Station
▲Zhangjiang National Innovation Demonstration Zone - Medical Big Data Public Service Platform
▲Zhangjiang National Innovation Demonstration Zone - Precision Medicine Demonstration Application Base
▲Shanghai High-tech Enterprise
▲Undertaker of Shanghai Precision Medicine Big Data Center
▲Shanghai "Four New" Economy Innovation Base

Baoteng has assembled a professional team, including 5 scientists, 6 academicians, and over 20 doctoral and postdoctoral researchers. It has also invited more than ten experts and scholars from the US FDA, Stanford University, Princeton University, City of Hope National Medical Center, and others. Using cutting-edge industry technologies, the company performs multi-dimensional integrated analysis and deep mining of big data constructed from multi-omics and clinical information of diseases, developing and establishing precision medicine and clinical application products for various diseases. The company provides systematic precision medical services to domestic and international medical institutions, corporate clients, and individuals, including early screening, risk assessment, precise typing, precision treatment, efficacy monitoring, and prognosis judgment for tumors, cardiovascular diseases, infectious diseases, maternal and child diseases, and other diseases.

In 2018, Baoteng Biomedical formally entered the gut microbiome track. In terms of innovative diagnosis and treatment, relying on the national first public service platform for gut microbiome diagnosis and treatment technology, the company has built a full-functional public service platform integrating cutting-edge microbiome research, standardized preparation of functional bacteria, and clinical practice. It has an autonomous intellectual property system for fecal microbiota transplantation technology, forming a full-process service system covering precise assessment, precise matching, precise preparation of microbiota, and clinical demonstration application. It has led and participated in the formulation of 6 expert consensus documents and 2 industry standards, establishing its position as a standard-setter in the field of microbiome diagnosis and treatment, and continuously promoting the standardized and high-quality development of the industry.

The company owns 5 office buildings covering an area of 16,000 square meters, used for experiments, testing, R&D, big data, and incubation. It has established nearly one hundred molecular medicine centers in benchmark top-tier hospitals and research institutions across China, with laboratory space exceeding 25,000 square meters. It develops and produces diagnostic reagents with independent intellectual property, early diagnosis reagents for major diseases, screens and validates new targeted molecular drugs, and quickly transforms them into production to meet the growing health needs of the Chinese people. It promotes the development of related biomedical industries in China, enhances the core competitiveness of China in the high-tech biomedical field, and provides an ideal industrial platform for cooperation and competition with world-renowned multinational companies in the field of personalized medicine.

We sincerely welcome elites in the biomedical field from home and abroad to join our team, jointly building a powerful engine and propeller for accelerating the transformation of Shanghai Zhangjiang into the "International Biomedical Valley" and the national precision medicine big data center!